576 related articles for article (PubMed ID: 28634084)
1. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
[TBL] [Abstract][Full Text] [Related]
2. Challenges in the delivery of therapies to melanoma brain metastases.
Gampa G; Vaidhyanathan S; Resman BW; Parrish KE; Markovic SN; Sarkaria JN; Elmquist WF
Curr Pharmacol Rep; 2016 Dec; 2(6):309-325. PubMed ID: 28546917
[TBL] [Abstract][Full Text] [Related]
3. The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions.
Murrell J; Board R
Cancer Treat Rev; 2013 Dec; 39(8):833-8. PubMed ID: 23845462
[TBL] [Abstract][Full Text] [Related]
4. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
Parrish KE; Sarkaria JN; Elmquist WF
Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
[TBL] [Abstract][Full Text] [Related]
5. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M; Kizilbash SH; Laramy JK; Gampa G; Parrish KE; Sarkaria JN; Elmquist WF
Pharm Res; 2018 Jul; 35(9):177. PubMed ID: 30003344
[TBL] [Abstract][Full Text] [Related]
6. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
8. Advances in the systemic treatment of melanoma brain metastases.
Glitza Oliva IC; Schvartsman G; Tawbi H
Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
[TBL] [Abstract][Full Text] [Related]
9. The role of systemic therapy in melanoma brain metastases: a narrative review.
Saleem K; Davar D
Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
[TBL] [Abstract][Full Text] [Related]
10. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
11. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
12. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
13. The role of systemic therapies in the management of melanoma brain metastases.
Lyle M; Long GV
Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
[TBL] [Abstract][Full Text] [Related]
14. Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Mohammad AS; Parrish KE; Mladek AC; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2019 Mar; 368(3):446-461. PubMed ID: 30622172
[TBL] [Abstract][Full Text] [Related]
15. New Era in the Management of Melanoma Brain Metastases.
Tawbi HA; Boutros C; Kok D; Robert C; McArthur G
Am Soc Clin Oncol Educ Book; 2018 May; 38():741-750. PubMed ID: 30231345
[TBL] [Abstract][Full Text] [Related]
16. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
Patel KR; Lawson DH; Kudchadkar RR; Carthon BC; Oliver DE; Okwan-Duodu D; Ahmed R; Khan MK
Neuro Oncol; 2015 Oct; 17(10):1312-21. PubMed ID: 26014049
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
18. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
19. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
20. Molecular insights into melanoma brain metastases.
Westphal D; Glitza Oliva IC; Niessner H
Cancer; 2017 Jun; 123(S11):2163-2175. PubMed ID: 28543697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]